Navigation Links
TEI Biosciences' PriMatrix(TM) Awarded Seal of Approval by American Podiatric Medical Association
Date:2/18/2010

BOSTON, Feb. 18 /PRNewswire/ -- TEI Biosciences Inc. announced today that its PriMatrix™ Dermal Repair Scaffold has been awarded the coveted American Podiatric Medical Association's (APMA) Seal of Approval.  PriMatrix is a bioactive collagen matrix used in the management of diabetic and venous ulcers, second-degree burns, and surgical and trauma wounds.

APMA is the nation's leading professional society for foot and ankle specialists. The Seal of Approval Program was created to inform podiatric physicians and consumers about products whose quality, safety, and effectiveness promote good foot health.  In order to qualify for the Seal of Approval, PriMatrix had to pass a thorough scientific evaluation by a panel of APMA members. The results were then evaluated by a committee of Doctors of Podiatric Medicine who decided to grant TEI the use of the Seal for PriMatrix.

"TEI is very excited about APMA's Seal of Approval award for PriMatrix," said Yiannis Monovoukas, Ph.D., TEI's Chairman, President and CEO.  "PriMatrix is a novel biologic product proven safe and effective in treating many types of skin wounds in several thousand patients," said Dr. Monovoukas.  "The addition of the APMA's Seal of Approval to PriMatrix is an affirmation of our commitment to developing innovative healthcare products that better meet the needs of physicians and their patients."  

About PriMatrix™ Dermal Repair Scaffold

PriMatrixDermal Repair Scaffold is an acellular collagen matrix derived from fetal bovine dermis, one of the purest forms of collagen available. Due to its bioactive collagen matrix technology, PriMatrix is an ideal material for the management of numerous types of wounds as it supports cell repopulation and revascularization processes essential to wound healing. PriMatrix is rich in Type III collagen, a natural component of fetal dermis that aids in tissue healing and regeneration.

PriMatrix is intended for the management of wounds that include: partial and full thickness wounds; pressure, diabetic, and venous ulcers; second-degree burns; surgical wounds; trauma wounds; tunneled/undermined wounds; and draining wounds.  

For more information, please visit TEI's website at www.teibio.com.

About TEI Biosciences Inc.

A Boston-based, privately-held, leading biomedical company, TEI Biosciences Inc. has applied its expertise in regenerative medicine to develop and commercialize novel biologic products for a broad spectrum of soft tissue repair, regeneration, and reinforcement applications -- from plastic and reconstructive surgery to dura, tendon, and hernia repair, and wound management.

TEI sells its products directly and through partnerships with some of the world's major medical device companies.  TEI's marketed products include:

  • SurgiMend® for plastic and reconstructive surgery, breast reconstruction, muscle flap reinforcement, hernia repair, and abdominal wall reconstruction;
  • PriMatrix™ for skin wound management;
  • Durepair® for cranial and spinal dura mater repair (marketed by Medtronic);
  • Xenform™  for pelvic floor reconstruction (marketed by Boston Scientific);
  • TissueMend® for tendon augmentation (marketed by Stryker).

SOURCE TEI Biosciences Inc.

RELATED LINKS
http://www.teibio.com

'/>"/>

SOURCE TEI Biosciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. YM BioSciences presents CYT387 and CYT997 data at international cancer conference
2. YM BioSciences granted two US patents for AeroLEF(R)
3. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
4. YM BioSciences reports second quarter 2010 operational and financial results
5. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
6. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
7. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
8. Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
9. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
10. YM BioSciences announces result of Cytopia shareholder vote
11. Profectus Biosciences to Present at Key Investor Conference in January 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... At its national board meeting in ... Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology ... in ARCS Alumni Hall of Fame . ASTER Labs is a technology ...
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking events ... announced today. The bold new look is part of a transformation to increase ... a significant growth period. , It will also expand its service offering from its ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
Breaking Biology News(10 mins):